HRP20180917T1 - Novi fragmenti protutijela, pripravci i njihova upotreba - Google Patents
Novi fragmenti protutijela, pripravci i njihova upotreba Download PDFInfo
- Publication number
- HRP20180917T1 HRP20180917T1 HRP20180917TT HRP20180917T HRP20180917T1 HR P20180917 T1 HRP20180917 T1 HR P20180917T1 HR P20180917T T HRP20180917T T HR P20180917TT HR P20180917 T HRP20180917 T HR P20180917T HR P20180917 T1 HRP20180917 T1 HR P20180917T1
- Authority
- HR
- Croatia
- Prior art keywords
- heavy chain
- human
- light chain
- domain
- variable domain
- Prior art date
Links
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title claims 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title claims 18
- 239000000203 mixture Substances 0.000 title 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 9
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 206010027476 Metastases Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000003831 deregulation Effects 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. Fragment protutijela, naznačen time što sadrži prvi polipeptid koji sadrži varijabilnu domenu lakog lanca i dvije konstantne domene i drugi polipeptid koji sadrži varijabilnu domenu teškog lanca i dvije konstantne domene, gdje su dvije konstantne domene konstantne domene lakog lanca, a dvije konstantne domene su konstantne domene CH1 teškog lanca, gdje navedeni fragment protutijela ima produljeni poluvijek in vivo u odnosu na Fab fragment koji sadrži navedene varijabilne domene lakog i teškog lanca,
gdje prvi polipeptid sadrži jednu varijabilnu domenu lakog lanca i dvije konstantne domene ljudskog lakog lanca, gdje je varijabilna domena lakog lanca fuzionirana s prvom konstantnom domenom ljudskog lakog lanca koja je fuzionirana s drugom konstantnom domenom lakog lanca u smjeru od N- do C-kraja, čime se dobije kimerni laki lanac VL-CL-CL, i
gdje drugi polipeptid sadrži jednu varijabilnu domenu teškog lanca i dvije konstantne domene ljudskog teškog lanca, gdje je varijabilna domena teškog lanca fuzionirana s prvom konstantnom domenom CH1 ljudskog teškog lanca koja je fuzionirana s drugom konstantnom domenom CH1 ljudskog teškog lanca u smjeru od N- do C-kraja, čime se dobije kimerni teški lanac VH-CH1-CH1.
2. Fragment protutijela, naznačen time što sadrži prvi polipeptid koji sadrži varijabilnu domenu lakog lanca i dvije konstantne domene i drugi polipeptid koji sadrži varijabilnu domenu teškog lanca i dvije konstantne domene, gdje su dvije konstantne domene konstantne domene lakog lanca, a dvije konstantne domene su konstantne domene CH1 teškog lanca, gdje navedeni fragment protutijela ima produljeni poluvijek in vivo u odnosu na Fab fragment koji sadrži navedene varijabilne domene lakog i teškog lanca,
gdje prvi polipeptid sadrži jednu varijabilnu domenu lakog lanca, jednu konstantnu domenu ljudskog lakog lanca i jednu ljudsku tešku konstantnu domenu CH1, gdje je varijabilna domena lakog lanca fuzionirana s konstantnom domenom ljudskog lakog lanca, a konstantna domena ljudskog lakog lanca je fuzionirana s konstantnom domenom CH1 ljudskog teškog lanca u smjeru od N- do C-kraja, čime se dobije kimerni laki lanac VL-CL-CH1, i
gdje drugi polipeptid sadrži jednu varijabilnu domenu teškog lanca, jednu konstantnu domenu CH1 ljudskog teškog lanca i jednu konstantnu domenu ljudskog lakog lanca, gdje je varijabilna domena teškog lanca fuzionirana s konstantnom domenom CH1 ljudskog teškog lanca, a konstantna domena CH1 ljudskog teškog lanca je fuzionirana s konstantnom domenom ljudskog lakog lanca u smjeru od N- do C-kraja, čime se dobije kimerni teški lanac VH-CH1-CL.
3. Fragment protutijela u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što se navedenu varijabilnu domenu lakog lanca bira između varijabilne domene neljudskog lakog lanca ili varijabilne domene ljudskog ili humaniziranog lakog lanca koja sadrži područja za određivanje komplementarnosti (CDR) iz neljudskog protutijela.
4. Fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se navedenu varijabilnu domenu teškog lanca bira između varijabilne domene neljudskog teškog lanca ili varijabilne domene ljudskog ili humaniziranog teškog lanca koja sadrži područja za određivanje komplementarnosti (CDR) iz neljudskog protutijela.
5. Fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je konstantna domena lakog lanca konstantna domena ljudskog lakog lanca kapa.
6. Fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je konstantna domena CH1 teškog lanca konstantna domena CH1 ljudskog teškog lanca gama.
7. Fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je konstantna domena CH1 teškog lanca iz ljudskog IgG1.
8. Fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se navedeni fragment protutijela specifično veže na receptor čimbenika rasta hepatocita (HGFR).
9. Fragment protutijela u skladu s patentnim zahtjevima 3 i 4, naznačen time što varijabilna domena humaniziranog lakog lanca sadrži područja za određivanje komplementarnosti (CDR) sa sljedovima iznijetim u SEQ ID No.: 25, 27 i 29, a varijabilna domena humaniziranog teškog lanca sadrži područja za određivanje komplementarnosti (CDR) sa sljedovima iznijetim u SEQ ID No.: 19, 21 i 23.
10. Farmaceutski pripravak, naznačen time što sadrži fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9, kao i farmaceutski prihvatljiv nosač.
11. Fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u liječenju pacijenta koji boluje od tumora i/ili metastaze.
12. Fragment protutijela namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što su navedeni tumor i/ili metastaza povezani s dereguliranjem signaliziranja i/ili aktiviranja HGFR.
13. Proizvod, naznačen time što sadrži fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9 i najmanje jedan od inhibitora HGF i inhibitora HGFR, kao kombinirani pripravak za istodobnu, odvojenu ili uzastopnu upotrebu u liječenju tumora i/ili metastaza, gdje su po mogućnosti tumor i/ili metastaza povezani s dereguliranjem signaliziranja i/ili aktiviranja HGFR.
14. Proizvod namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što najmanje jedan inhibitor se bira između protutijela protiv HGF, rekombinantnih molekula koje se natječu s HGF, niskomolekulskih inhibitora HGFR, protutijela protiv HGFR ili inhibitora HGFR.
15. Izolirana nukleinska kiselina koja kodira fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
16. Vektor, naznačen time što u najmanju ruku sadrži nukleotidni slijed koji kodira fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
17. Pripravak, naznačen time što sadrži dva ili više nukleinskih kiselina koje kodiraju fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
18. Izolirana nukleinska kiselina u skladu s patentnim zahtjevom 15, vektor u skladu s patentnim zahtjevom 16, ili pripravak u skladu s patentnim zahtjevom 17, naznačeni time što su namijenjeni upotrebi u liječenju pacijenta koji boluje od tumora i/ili metastaze, gdje su po mogućnosti tumor i/ili metastaza povezani s dereguliranjem signaliziranja i/ili aktiviranja HGFR.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000012A ITTO20130012A1 (it) | 2013-01-09 | 2013-01-09 | Nuovi frammenti anticorpali, relative composizioni ed usi |
| PCT/IB2014/058098 WO2014108829A1 (en) | 2013-01-09 | 2014-01-07 | New antibody fragments, compositions and uses thereof |
| EP14701430.2A EP2943510B1 (en) | 2013-01-09 | 2014-01-07 | New antibody fragments, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180917T1 true HRP20180917T1 (hr) | 2018-08-10 |
Family
ID=47790367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180917TT HRP20180917T1 (hr) | 2013-01-09 | 2018-06-13 | Novi fragmenti protutijela, pripravci i njihova upotreba |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9975952B2 (hr) |
| EP (1) | EP2943510B1 (hr) |
| JP (1) | JP6382842B2 (hr) |
| KR (1) | KR102155392B1 (hr) |
| CN (1) | CN104968684B (hr) |
| AU (1) | AU2014206130A1 (hr) |
| BR (1) | BR112015016447A8 (hr) |
| CA (1) | CA2896929C (hr) |
| CL (1) | CL2015001939A1 (hr) |
| DK (1) | DK2943510T3 (hr) |
| EA (1) | EA031536B1 (hr) |
| ES (1) | ES2674491T3 (hr) |
| HR (1) | HRP20180917T1 (hr) |
| HU (1) | HUE037843T2 (hr) |
| IL (1) | IL239704B (hr) |
| IT (1) | ITTO20130012A1 (hr) |
| LT (1) | LT2943510T (hr) |
| ME (1) | ME03080B (hr) |
| MX (1) | MX360258B (hr) |
| PH (1) | PH12015501539A1 (hr) |
| PL (1) | PL2943510T3 (hr) |
| PT (1) | PT2943510T (hr) |
| RS (1) | RS57286B1 (hr) |
| SG (1) | SG11201505114VA (hr) |
| SI (1) | SI2943510T1 (hr) |
| TR (1) | TR201808826T4 (hr) |
| WO (1) | WO2014108829A1 (hr) |
| ZA (1) | ZA201504748B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800003875A1 (it) * | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| KR102433184B1 (ko) * | 2018-12-07 | 2022-08-17 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| KR102396194B1 (ko) * | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| CN113480645B (zh) * | 2021-07-16 | 2022-11-11 | 甘肃中科博瑞生物工程有限公司 | 一种抗幽门螺旋杆菌重组抗体、制备方法及用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
| US7476724B2 (en) * | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| UA94213C2 (ru) * | 2004-09-17 | 2011-04-26 | Домантис Лимитед | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания |
| SG169382A1 (en) * | 2006-02-06 | 2011-03-30 | Metheresis Translational Res S A Ch | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| CN103183738B (zh) * | 2006-03-30 | 2014-08-06 | 诺瓦提斯公司 | c-Met抗体的组合物和使用方法 |
| EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
| US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| ES2720136T3 (es) * | 2010-12-22 | 2019-07-18 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpo modificado con semivida mejorada |
| HUE039703T2 (hu) * | 2011-08-23 | 2019-01-28 | Roche Glycart Ag | Bispecifikus antigénkötõ molekulák |
-
2013
- 2013-01-09 IT IT000012A patent/ITTO20130012A1/it unknown
-
2014
- 2014-01-07 LT LTEP14701430.2T patent/LT2943510T/lt unknown
- 2014-01-07 SI SI201430756T patent/SI2943510T1/en unknown
- 2014-01-07 BR BR112015016447A patent/BR112015016447A8/pt not_active IP Right Cessation
- 2014-01-07 WO PCT/IB2014/058098 patent/WO2014108829A1/en active Application Filing
- 2014-01-07 ME MEP-2018-157A patent/ME03080B/me unknown
- 2014-01-07 HU HUE14701430A patent/HUE037843T2/hu unknown
- 2014-01-07 MX MX2015008779A patent/MX360258B/es active IP Right Grant
- 2014-01-07 CA CA2896929A patent/CA2896929C/en active Active
- 2014-01-07 DK DK14701430.2T patent/DK2943510T3/en active
- 2014-01-07 EA EA201591279A patent/EA031536B1/ru not_active IP Right Cessation
- 2014-01-07 PL PL14701430T patent/PL2943510T3/pl unknown
- 2014-01-07 SG SG11201505114VA patent/SG11201505114VA/en unknown
- 2014-01-07 PT PT147014302T patent/PT2943510T/pt unknown
- 2014-01-07 RS RS20180668A patent/RS57286B1/sr unknown
- 2014-01-07 ES ES14701430.2T patent/ES2674491T3/es active Active
- 2014-01-07 TR TR2018/08826T patent/TR201808826T4/tr unknown
- 2014-01-07 CN CN201480007855.5A patent/CN104968684B/zh active Active
- 2014-01-07 EP EP14701430.2A patent/EP2943510B1/en active Active
- 2014-01-07 JP JP2015551243A patent/JP6382842B2/ja active Active
- 2014-01-07 KR KR1020157021325A patent/KR102155392B1/ko active IP Right Grant
- 2014-01-07 US US14/758,079 patent/US9975952B2/en active Active
- 2014-01-07 AU AU2014206130A patent/AU2014206130A1/en not_active Abandoned
-
2015
- 2015-06-29 IL IL239704A patent/IL239704B/en active IP Right Grant
- 2015-07-01 ZA ZA201504748A patent/ZA201504748B/en unknown
- 2015-07-08 CL CL2015001939A patent/CL2015001939A1/es unknown
- 2015-07-08 PH PH12015501539A patent/PH12015501539A1/en unknown
-
2018
- 2018-04-13 US US15/952,513 patent/US10351628B2/en active Active
- 2018-06-13 HR HRP20180917TT patent/HRP20180917T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180917T1 (hr) | Novi fragmenti protutijela, pripravci i njihova upotreba | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| ES2806500T3 (es) | Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas | |
| ES2742287T3 (es) | Anticuerpos monoclonales contra el factor de diferenciación de crecimiento 15 (GDF-15) | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| Fischer et al. | Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies | |
| JP2021106617A5 (hr) | ||
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| ES2965626T3 (es) | Anticuerpos monoclonales contra el factor 15 de diferenciación y crecimiento (GDF-15), y usos de los mismos para tratar la caquexia por cáncer y el cáncer | |
| RU2017134140A (ru) | Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования | |
| JP2015529641A5 (hr) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2018512145A5 (hr) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2015509938A5 (hr) | ||
| IL299072A (en) | Antibodies and methods for using them | |
| HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| JP2015506912A5 (hr) | ||
| CN105457024B (zh) | 抗butyrophilin-3人源化抗体及其使用 | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака |